爱施德：2025年前三季度净利润约3.37亿元

Group 1: Company Performance - Aishide reported a revenue of approximately 39.375 billion yuan for the first three quarters of 2025, representing a year-on-year decrease of 31.47% [1] - The net profit attributable to shareholders of the listed company was approximately 337 million yuan, down 35.78% year-on-year [1] - The basic earnings per share were 0.2721 yuan, reflecting a decrease of 35.76% compared to the previous year [1] Group 2: Market Context - As of the report, Aishide's market capitalization stood at 15.9 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion US dollars this year [2] - There is a contrast in the biopharmaceutical market, where the secondary market is thriving while the primary market is facing challenges in fundraising [2]